Alithea Genomics announces the successful closure of their Seed Financing Extension, securing CHF 2.8 Million ($3.2 Million) led by Novalis Biotech Acceleration fund, with participation from TECHU Ventures and existing investors.
This milestone marks a significant step forward in their journey to revolutionize large-scale RNA sequencing and transcriptomics. With this funding, they are poised to embark on an ambitious path towards innovation and growth.
What does this mean for Alithea Genomics?
Launching New RNA Sequencing Products: They’re gearing up to introduce cutting-edge RNA sequencing solutions to the market, empowering researchers with enhanced capabilities and efficiency.
Expanding Production Capacity: With increased resources, they’ll bolster their manufacturing capacity to meet the growing demand for their unique products.
Developing New Technologies: Innovation is at the core of their mission. The funding will fuel their efforts in advancing novel technologies that push the boundaries of RNA sequencing.
Opening a US Subsidiary: They’re excited to announce the establishment of their subsidiary in the United States, strengthening their global presence and enabling closer collaboration with their partners and customers.
